(Total Views: 116)
Posted On: 12/19/2023 9:11:23 PM
Post# of 6
UPDATE 1-US FDA declines to approve Checkpoint Therapeutics' skin cancer therapy
1
Mon, December 18, 2023 at 7:31 AM EST
In this article:
CKPT
-4.37%
(Adds background on therapy throughout)
Dec 18 (Reuters) - Checkpoint Therapeutics said on Monday the U.S. Food and Drug Administration declined to approve its experimental therapy to treat a type of advanced skin cancer, citing issues related to a third-party contract manufacturer.
The company filed the marketing application for the drug, Cosibelimab, its lead therapy in development, earlier this year.
1
Mon, December 18, 2023 at 7:31 AM EST
In this article:
CKPT
-4.37%
(Adds background on therapy throughout)
Dec 18 (Reuters) - Checkpoint Therapeutics said on Monday the U.S. Food and Drug Administration declined to approve its experimental therapy to treat a type of advanced skin cancer, citing issues related to a third-party contract manufacturer.
The company filed the marketing application for the drug, Cosibelimab, its lead therapy in development, earlier this year.
(0)
(0)Scroll down for more posts ▼
